ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Clomid for PCT, fertility or low T
Pharmacodynamics and Safety of Human Recombinant LH in HH Men
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 207938" data-attributes="member: 13851"><p>Definitely looking forward to this!</p><p></p><p></p><p></p><p></p><p><strong>Anticipated Study Start Date: <em>Oct 1, 2021</em></strong></p><p><strong></strong></p><p><strong>Anticipated Study Completion: <em>Oct 1, 2023</em></strong></p><p></p><p>[ATTACH=full]16359[/ATTACH]</p><p></p><p></p><p></p><p></p><h3>OUTCOME MEASURES</h3><h4><strong>PRIMARY OUTCOME MEASURES</strong></h4> <ol> <li data-xf-list-type="ol">Testosterone [2 weeks after treatment start]<br /> total testosterone serum levels</li> <li data-xf-list-type="ol">Testosterone [4 weeks after treatment start]<br /> total testosterone serum levels</li> <li data-xf-list-type="ol">Testosterone [6 weeks after treatment start]<br /> total testosterone serum levels</li> <li data-xf-list-type="ol"><strong><u>Testosterone</u> [8 weeks after treatment start]<br /> <u>total testosterone serum levels</u></strong></li> </ol><h4><strong>SECONDARY OUTCOME MEASURES</strong></h4> <ol> <li data-xf-list-type="ol">Inhibin B [2 weeks after treatment start]<br /> Inhibin B serum levels</li> <li data-xf-list-type="ol">Inhibin B [4 weeks after treatment start]<br /> Inhibin B serum levels</li> <li data-xf-list-type="ol">Inhibin B [6 weeks after treatment start]<br /> Inhibin B serum levels</li> <li data-xf-list-type="ol"><strong><u>Inhibin B</u> [8 weeks after treatment start]<br /> <u>Inhibin B serum levels</u></strong></li> <li data-xf-list-type="ol">Free testosterone [2 weeks after treatment start]<br /> Free testosterone serum levels</li> <li data-xf-list-type="ol">Free testosterone [4 weeks after treatment start]<br /> Free testosterone serum levels</li> <li data-xf-list-type="ol">Free testosterone [6 weeks after treatment start]<br /> Free testosterone serum levels</li> <li data-xf-list-type="ol"><strong><u>Free testosterone</u> [8 weeks after treatment start]<br /> <u>Free testosterone serum levels</u></strong></li> <li data-xf-list-type="ol">SHBG [2 weeks after treatment start]<br /> sex hormone-binding globulin (SHBG)</li> <li data-xf-list-type="ol">SHBG [4 weeks after treatment start]<br /> sex hormone-binding globulin (SHBG)</li> <li data-xf-list-type="ol">SHBG [6 weeks after treatment start]<br /> sex hormone-binding globulin (SHBG)</li> <li data-xf-list-type="ol"><strong><u>SHBG</u> [8 weeks after treatment start]<br /> <u>sex hormone-binding globulin (SHBG)</u></strong></li> <li data-xf-list-type="ol">Estradiol [2 weeks after treatment start]<br /> Estradiol serum levels by LC-MS/MS evaluation</li> <li data-xf-list-type="ol">Estradiol [4 weeks after treatment start]<br /> Estradiol serum levels by LC-MS/MS evaluation</li> <li data-xf-list-type="ol">Estradiol [6 weeks after treatment start]<br /> Estradiol serum levels by LC-MS/MS evaluation</li> <li data-xf-list-type="ol"><strong><u>Estradiol</u> [8 weeks after treatment start]<br /> <u>Estradiol serum levels by LC-MS/MS evaluation</u></strong></li> <li data-xf-list-type="ol">LH [2 weeks after treatment start]<br /> Serum LH</li> <li data-xf-list-type="ol">LH [4 weeks after treatment start]<br /> Serum LH</li> <li data-xf-list-type="ol">LH [6 weeks after treatment start]<br /> Serum LH</li> <li data-xf-list-type="ol"><strong><u>LH</u> [8 weeks after treatment start]<br /> <u>Serum LH</u></strong></li> <li data-xf-list-type="ol">FSH [2 weeks after treatment start]<br /> Serum FSH</li> <li data-xf-list-type="ol">FSH [4 weeks after treatment start]<br /> Serum FSH</li> <li data-xf-list-type="ol">FSH [6 weeks after treatment start]<br /> Serum FSH</li> <li data-xf-list-type="ol"><strong><u>FSH</u> [8 weeks after treatment start]<br /> <u>Serum FSH</u></strong></li> </ol><h4><strong>OTHER OUTCOME MEASURES</strong></h4> <ol> <li data-xf-list-type="ol">Steroids [2 weeks after treatment start]<br /> Other steroids provided by the LC-MS/MS methodology</li> <li data-xf-list-type="ol">Steroids [4 weeks after treatment start]<br /> Other steroids provided by the LC-MS/MS methodology</li> <li data-xf-list-type="ol">Steroids [6 weeks after treatment start]<br /> Other steroids provided by the LC-MS/MS methodology</li> <li data-xf-list-type="ol"><strong><u>Steroids</u> [8 weeks after treatment start]<br /> <u>Other steroids provided by the LC-MS/MS methodology</u></strong></li> <li data-xf-list-type="ol">Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [2 weeks after treatment start]<br /> This was evaluated considering red blood cell count, marker of liver function, markers of coagulation.</li> <li data-xf-list-type="ol">Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [4 weeks after treatment start]<br /> This was evaluated considering red blood cell count, marker of liver function, markers of coagulation.</li> <li data-xf-list-type="ol">Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [6 weeks after treatment start]<br /> This was evaluated considering red blood cell count, marker of liver function, markers of coagulation.</li> <li data-xf-list-type="ol"><strong><u>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</u> [8 weeks after treatment start]<br /> <u>This was evaluated considering red blood cell count, marker of liver function, markers of coagulation</u>.</strong></li> <li data-xf-list-type="ol">Testicular volume [Baseline]<br /> The testicular volume will be assessed locally at each visit by a physician blind to the patient group allocation</li> <li data-xf-list-type="ol"><strong><u>Testicular volume</u> [8 weeks after treatment start]<br /> <u>The testicular volume will be assessed locally at each visit by a physician blind to the patient group allocation</u>.</strong></li> </ol></blockquote><p></p>
[QUOTE="madman, post: 207938, member: 13851"] Definitely looking forward to this! [B]Anticipated Study Start Date: [I]Oct 1, 2021[/I] Anticipated Study Completion: [I]Oct 1, 2023[/I][/B] [ATTACH type="full" alt="Screenshot (7009).png"]16359[/ATTACH] [HEADING=2]OUTCOME MEASURES[/HEADING] [HEADING=3][B]PRIMARY OUTCOME MEASURES[/B][/HEADING] [LIST=1] [*]Testosterone [2 weeks after treatment start] total testosterone serum levels [*]Testosterone [4 weeks after treatment start] total testosterone serum levels [*]Testosterone [6 weeks after treatment start] total testosterone serum levels [*][B][U]Testosterone[/U] [8 weeks after treatment start] [U]total testosterone serum levels[/U][/B] [/LIST] [HEADING=3][B]SECONDARY OUTCOME MEASURES[/B][/HEADING] [LIST=1] [*]Inhibin B [2 weeks after treatment start] Inhibin B serum levels [*]Inhibin B [4 weeks after treatment start] Inhibin B serum levels [*]Inhibin B [6 weeks after treatment start] Inhibin B serum levels [*][B][U]Inhibin B[/U] [8 weeks after treatment start] [U]Inhibin B serum levels[/U][/B] [*]Free testosterone [2 weeks after treatment start] Free testosterone serum levels [*]Free testosterone [4 weeks after treatment start] Free testosterone serum levels [*]Free testosterone [6 weeks after treatment start] Free testosterone serum levels [*][B][U]Free testosterone[/U] [8 weeks after treatment start] [U]Free testosterone serum levels[/U][/B] [*]SHBG [2 weeks after treatment start] sex hormone-binding globulin (SHBG) [*]SHBG [4 weeks after treatment start] sex hormone-binding globulin (SHBG) [*]SHBG [6 weeks after treatment start] sex hormone-binding globulin (SHBG) [*][B][U]SHBG[/U] [8 weeks after treatment start] [U]sex hormone-binding globulin (SHBG)[/U][/B] [*]Estradiol [2 weeks after treatment start] Estradiol serum levels by LC-MS/MS evaluation [*]Estradiol [4 weeks after treatment start] Estradiol serum levels by LC-MS/MS evaluation [*]Estradiol [6 weeks after treatment start] Estradiol serum levels by LC-MS/MS evaluation [*][B][U]Estradiol[/U] [8 weeks after treatment start] [U]Estradiol serum levels by LC-MS/MS evaluation[/U][/B] [*]LH [2 weeks after treatment start] Serum LH [*]LH [4 weeks after treatment start] Serum LH [*]LH [6 weeks after treatment start] Serum LH [*][B][U]LH[/U] [8 weeks after treatment start] [U]Serum LH[/U][/B] [*]FSH [2 weeks after treatment start] Serum FSH [*]FSH [4 weeks after treatment start] Serum FSH [*]FSH [6 weeks after treatment start] Serum FSH [*][B][U]FSH[/U] [8 weeks after treatment start] [U]Serum FSH[/U][/B] [/LIST] [HEADING=3][B]OTHER OUTCOME MEASURES[/B][/HEADING] [LIST=1] [*]Steroids [2 weeks after treatment start] Other steroids provided by the LC-MS/MS methodology [*]Steroids [4 weeks after treatment start] Other steroids provided by the LC-MS/MS methodology [*]Steroids [6 weeks after treatment start] Other steroids provided by the LC-MS/MS methodology [*][B][U]Steroids[/U] [8 weeks after treatment start] [U]Other steroids provided by the LC-MS/MS methodology[/U][/B] [*]Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [2 weeks after treatment start] This was evaluated considering red blood cell count, marker of liver function, markers of coagulation. [*]Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [4 weeks after treatment start] This was evaluated considering red blood cell count, marker of liver function, markers of coagulation. [*]Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [6 weeks after treatment start] This was evaluated considering red blood cell count, marker of liver function, markers of coagulation. [*][B][U]Number of participants with treatment-related adverse events as assessed by CTCAE v4.0[/U] [8 weeks after treatment start] [U]This was evaluated considering red blood cell count, marker of liver function, markers of coagulation[/U].[/B] [*]Testicular volume [Baseline] The testicular volume will be assessed locally at each visit by a physician blind to the patient group allocation [*][B][U]Testicular volume[/U] [8 weeks after treatment start] [U]The testicular volume will be assessed locally at each visit by a physician blind to the patient group allocation[/U].[/B] [/LIST] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Clomid for PCT, fertility or low T
Pharmacodynamics and Safety of Human Recombinant LH in HH Men
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top